Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
PHAT

PHAT - Phathom Pharmaceuticals Inc Stock Price, Fair Value and News

10.94USD-0.24 (-2.15%)Market Closed

Market Summary

PHAT
USD10.94-0.24
Market Closed
-2.15%

PHAT Alerts

  • 2 major insider sales recently.

PHAT Stock Price

View Fullscreen

PHAT RSI Chart

PHAT Valuation

Market Cap

640.4M

Price/Earnings (Trailing)

-2.6

Price/Sales (Trailing)

1.0K

Price/Free Cashflow

-3.8

PHAT Price/Sales (Trailing)

PHAT Profitability

Operating Margin

75.51%

Return on Equity

166.08%

Return on Assets

-69.18%

Free Cashflow Yield

-26.3%

PHAT Fundamentals

PHAT Revenue

Revenue (TTM)

682.0K

PHAT Earnings

Earnings (TTM)

-246.6M

Earnings Growth (Yr)

-119.1%

Earnings Growth (Qtr)

-4.12%

Breaking Down PHAT Revenue

Last 7 days

-6.1%

Last 30 days

-7.8%

Last 90 days

22.0%

Trailing 12 Months

-22.2%

How does PHAT drawdown profile look like?

PHAT Financial Health

Current Ratio

7.83

Debt/Equity

-1

Debt/Cashflow

-1.12

PHAT Investor Care

Shares Dilution (1Y)

34.21%

Diluted EPS (TTM)

-4.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
2023000682.0K
20220000

Tracking the Latest Insider Buys and Sells of Phathom Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 15, 2024
nabulsi azmi
sold
-127,760
11.72
-10,901
chief operating officer
Jul 15, 2024
henderson molly
sold
-50,689
11.72
-4,325
cfo and cbo
Jul 15, 2024
curran terrie
sold
-396,699
11.72
-33,848
president and chief executive
May 31, 2024
henderson molly
acquired
-
-
7,500
cfo and cbo
May 31, 2024
nabulsi azmi
acquired
-
-
7,500
chief operating officer
May 29, 2024
karbe frank
acquired
254,112
10.1645
25,000
-
May 23, 2024
cola michael f
acquired
-
-
10,500
-
May 23, 2024
fields heidi
acquired
-
-
10,500
-
May 23, 2024
topper james n
acquired
-
-
10,500
-
May 23, 2024
stenhouse mark
acquired
-
-
10,500
-

1–10 of 50

Which funds bought or sold PHAT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 16, 2024
Medicxi Ventures Management (Jersey) Ltd
unchanged
-
-2,388,660
76,885,100
22.93%
Jul 15, 2024
Occidental Asset Management, LLC
unchanged
-
-9,495
305,622
0.05%
Jul 15, 2024
LVW Advisors, LLC
new
-
132,963
132,963
0.02%
Jul 12, 2024
SG Americas Securities, LLC
sold off
-100
-200,000
-
-%
Jul 12, 2024
INSPIRION WEALTH ADVISORS, LLC
added
4.27
4,207
377,330
0.06%
Jul 10, 2024
CWM, LLC
added
100
-
-
-%
Jul 09, 2024
ZRC WEALTH MANAGEMENT, LLC
unchanged
-
-7.00
206
-%
Jul 02, 2024
GAMMA Investing LLC
reduced
-69.57
-172
72.00
-%
Jul 01, 2024
Legal & General Group Plc
reduced
-0.44
49,436
362,164
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
65.85
56,703
116,703
0.01%

1–10 of 49

Are Funds Buying or Selling PHAT?

Are funds buying PHAT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PHAT
No. of Funds

Unveiling Phathom Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 06, 2024
frazier life sciences public fund, l.p.
10.0%
5,827,415
SC 13D/A
Apr 10, 2024
takeda pharmaceutical co ltd
4.8%
2,790,480
SC 13D/A
Apr 01, 2024
takeda pharmaceutical co ltd
5.4%
3,153,217
SC 13D/A
Feb 12, 2024
carlyle group inc.
6.1%
3,496,808
SC 13G/A
Feb 09, 2024
invesco ltd.
5.5%
3,167,653
SC 13G/A
Jan 26, 2024
medicxi growth i lp
6.4%
3,673,602
SC 13G/A
Jan 25, 2024
takeda pharmaceutical co ltd
6.6%
3,755,583
SC 13D/A
May 26, 2023
frazier life sciences public fund, l.p.
10.7%
5,827,415
SC 13D/A
May 05, 2023
frazier life sciences public fund, l.p.
13.4%
5,827,415
SC 13D/A
Mar 09, 2023
carlyle group inc.
6.7%
2,935,106
SC 13G

Recent SEC filings of Phathom Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jul 18, 2024
8-K
Current Report
Jul 17, 2024
4
Insider Trading
Jul 17, 2024
4
Insider Trading
Jul 17, 2024
4
Insider Trading
Jun 14, 2024
10-K/A
Annual Report
Jun 14, 2024
10-Q/A
Quarterly Report
Jun 06, 2024
SC 13D/A
13D - Major Acquisition
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading

Peers (Alternatives to Phathom Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Phathom Pharmaceuticals Inc News

Latest updates
American Banking and Market News69 minutes ago
American Banking and Market News24 hours ago
Investing.com17 Jul 202407:11 pm

Phathom Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q12022Q4
Revenue-1,912---
Cost Of Revenue-426---
Gross Profit-1,486---
Operating Expenses1.5%71,44070,39030,07746,642
  S&GA Expenses8.8%62,01056,99718,59830,696
  R&D Expenses-29.6%9,43013,39411,47915,946
Interest Expenses31.8%17,16813,0299,2179,602
Net Income-4.1%-82,852-79,570-37,814-55,047
Net Income Margin-22.3%-361.63*-295.59*--
Free Cashflow-56.0%-69,060-44,272-39,883-41,453
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Assets-13.9%35641423726514416520221414918922821524629523125226425780.00-
  Current Assets-14.4%34039722725814016119820914618722521124329122724926225678.001.00
    Cash Equivalents-15.5%32238121424913015519720713818322521023828722624725724474.001.00
  Inventory20.7%1.001.000.000.00----------------
  Net PPE-8.6%2.002.002.001.001.001.001.001.001.001.001.001.001.001.001.001.001.000.000.00-
Liabilities3.8%50548725524723424022822111111712582.0082.0010175.0064.0055.0029.00232-
  Current Liabilities12.1%43.0039.0024.0022.0014.0026.0023.0021.0011.0019.0028.0040.0041.0056.0028.0013.005.004.002072.00
  Long Term Debt8.1%14913899.0098.0097.0095.0094.0092.0091.0090.0088.0037.0036.0040.0041.0045.0046.0023.0023.00-
    LT Debt, Current------------10.0012.007.006.001.00----
    LT Debt, Non Current8.1%14913899.0098.0097.0095.0094.0092.0091.0090.0088.0037.0036.0040.0041.0045.00-23.00--
Shareholder's Equity-104.1%-148-72.76-18.00-90.19-74.81--38.0072.00103132164194156188209228--
  Retained Earnings-8.9%-1,011-928-849-805-764-727-672-620-570-529-493-456-420-385-331-297-276-256-158-1.29
  Additional Paid-In Capital0.8%8638568318236756526466146086025975895855804884864854846.000.00
Shares Outstanding1.0%59.0058.0057.0057.0042.0041.0039.0038.0038.0031.0037.0037.00--------
Float----526---198---684---552----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-57.6%-69,020-43,797-31,914-22,200-39,669-41,041-35,016-25,716-44,757-41,262-29,066-28,364-49,765-28,200-20,727-9,344-11,417-23,384-7,108-5,211-807
  Share Based Compensation-77.1%5,62624,5846,1407,2537,0486,6575,8165,8855,7754,3384,4194,2373,8182,3792,070828563----
Cashflow From Investing91.6%-40.00-475-939-6.00-214-412-134-428-67.00-100-14.00-45.00-169-124-183-57.00-676----
Cashflow From Financing-95.3%9,900211,99313.00141,50214,072-24,596--16344,02910441289,459--25,000192,771-1,299--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PHAT Income Statement

2023-12-31
Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Gross Profit [Abstract]  
Product revenue, net$ 682$ 0
Cost of revenue1670
Gross Profit5150
Operating expenses:  
Research and development (includes related party amounts of $760 and $2,123, respectively)49,89971,441
Selling, general and administrative (includes related party amounts of $55 and $0, respectively)117,928100,999
Total operating expenses167,827172,440
Loss from operations(167,312)(172,440)
Other income (expense):  
Interest income7,8762,132
Interest expense(41,968)(27,305)
Other (expense), net(188)(110)
Total other expense(34,280)(25,283)
Net loss and comprehensive loss$ (201,592)$ (197,723)
Net loss per share, basic$ (3.93)$ (5.05)
Net loss per share, diluted$ (3.93)$ (5.05)
Weighted-average shares of common stock outstanding, basic51,289,09239,118,215
Weighted-average shares of common stock outstanding, diluted51,289,09239,118,215

PHAT Balance Sheet

2023-12-31
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 381,393$ 155,385
Prepaid expenses and other current assets13,1945,127
Accounts receivable, net1,6370
Inventory1,2080
Total current assets397,432160,512
Property, plant and equipment, net2,1461,207
Operating lease right-of-use assets1,4752,287
Restricted cash2,863505
Inventory, noncurrent8,2340
Other long-term assets1,692299
Total assets413,842164,810
Current liabilities:  
Accounts payable (including related party amounts of $25 and $35 respectively)12,6019,997
Accrued expenses (including related party amountsof $2,694 and $2,499 respectively)17,19714,678
Accrued interest1,146854
Operating lease liabilities, current726708
Current portion of revenue interest financing liability7,1110
Total current liabilities38,78126,237
Long-term debt, net of discount137,84295,264
Revenue interest financing liability299,816109,525
Operating lease liabilities4621,098
Other long-term liabilities9,7007,500
Total liabilities486,601239,624
Commitments and contingencies (Note 4)
Stockholders' deficit:  
Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2023 and December 2022; no shares issued and outstanding at December 31, 2023 and December 2022
Common stock, $0.0001 par value; authorized shares - 400,000,000 at December 31, 2023 and December 2022; issued shares - 57,970,044 and 41,723,308 at December 31, 2023 and December 2022, respectively; outstanding shares - 57,970,044 and 41,468,871 at December 31, 2023 and December 2022, respectively53
Treasury stock - 19 shares at December 31, 2023 and December 2022 respectively00
Additional paid-in capital855,921652,276
Accumulated deficit(928,685)(727,093)
Total stockholders' deficit(72,759)(74,814)
Total liabilities and stockholders' deficit$ 413,842$ 164,810
PHAT
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
 CEO
 WEBSITEphathompharma.com
 INDUSTRYBiotechnology
 EMPLOYEES112

Phathom Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Phathom Pharmaceuticals Inc? What does PHAT stand for in stocks?

PHAT is the stock ticker symbol of Phathom Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Phathom Pharmaceuticals Inc (PHAT)?

As of Fri Jul 19 2024, market cap of Phathom Pharmaceuticals Inc is 640.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PHAT stock?

You can check PHAT's fair value in chart for subscribers.

What is the fair value of PHAT stock?

You can check PHAT's fair value in chart for subscribers. The fair value of Phathom Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Phathom Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PHAT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Phathom Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether PHAT is over valued or under valued. Whether Phathom Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Phathom Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PHAT.

What is Phathom Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, PHAT's PE ratio (Price to Earnings) is -2.6 and Price to Sales (PS) ratio is 1.04 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PHAT PE ratio will change depending on the future growth rate expectations of investors.